Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte models of hepatitis B
WuXi AppTec scientists recently contributed to a research study published in the journal Hepatology, characterizing the efficacy of prodrug DF-006 for treating chronic hepatitis B infection.
DF-006 is an orally active agonist of alpha‐kinase 1, a pattern recognition receptor involved in the stimulation of innate immunity. The authors show that DF‐006 is efficacious in hepatitis B virus mouse models, without any indications of overt toxicity.
You May Also Be Interested In
Discuss Your Program with Us
Share your development goals and key challenges with our experts to define the right path forward.